

Index

- 5-HT3 receptor antagonists, 212
- acetaminophen, 211, 255
- acetylsalicylic acid, 127
- acupuncture, 106, 210, 349
- acute inflammatory demyelinating polyneuropathy (AIDP), 135
- acyclovir, 121
- adenosine-5'-triphosphate (ATP), 77–9
- advanced glycosylation end products (AGEs), 103
- ajulemic acid (CT3), 255, 257
- alcohol
- as a coping strategy, 3
- alfentanil, 151
- allodynia, 52, 123, 151
- alpha adrenergic receptors
- drug targeting, 346
- alternative medicines and complementary therapies, 210
- amantadine, 151
- American Academy of Neurology, 243
- American Academy of Physical Medicine and Rehabilitation, 243
- American Association of Neuromuscular and Electrodiagnostic Medicine, 243
- American Pain Society, 225
- amitriptyline, 106–13, 125, 127, 150, 172, 212, 218–19, 295, 346
- AMPA receptor
- drug targeting, 345
- amphoterin (HMGB1), 93–4
- alpha-amylin, 255
- beta-amylin, 255
- anakinra, 82
- analgesic ladder, 192–3
- anandamide, 254–5
- anesthesia dolorosa
- animal model, 33–8
- anhedonia, 3
- animal models of neuropathic pain
- anesthesia dolorosa model, 33–8
 - autotomy model, 33–8
 - cannabinoid effects, 252–5
 - causalgia model, 38
 - central nerve injury models, 39
 - central post-stroke pain, 39
 - challenges in translational pain research, 44–7
 - chronic compression of the dorsal root ganglion, 39
 - chronic constriction nerve injury model, 38
 - combined drug therapies, 290–1
 - contribution of Nav1.3 channel, 70
 - contribution of Nav1.7 channel, 68–9
 - contribution of Nav1.8 channel, 69
 - contribution of Nav1.9 channel, 70
 - disease-related models, 39–41
 - distal symmetrical polyneuropathy, 41
 - experimental autoimmune encephalomyelitis (EAE) model, 160–3
 - interpreting results from animal models, 47–8
 - orofacial models, 41–4
 - partial nerve ligation model, 38
 - peripheral diabetic neuropathy, 41
 - peripheral nerve injury models, 33–9
 - range of models, 33
 - role in the study of neuropathic pain, 33
 - spared nerve injury model, 39
 - spinal cord injury, 39
 - spinal nerve ligation model, 38
 - spontaneous burning pain model, 38
 - Theiler's murine encephalitis virus (TMEV) model, 163
 - translation to humans, 85
 - trigeminal neuropathic pain, 41–4
 - variability between models, 44
 - vincristine-induced painful neuropathy, 41
- See also* inflammatory mediators.
- antalgic gait, 5
- anticonvulsants, 127, 231–6
- adjuvant analgesics for cancer pain, 200–1
 - for central post-stroke pain, 172
 - for fibromyalgia, 212
 - for painful diabetic sensorimotor polyneuropathy, 113
 - for spinal cord injury pain, 150–1
 - neuropathic pain studies, 346
 - use in neuropathic pain treatment, 225
- See also* gabapentinoids *and* specific drugs.
- antidepressants, 127
- adjuvant analgesics for cancer pain, 197–200
 - analgesics, 121
 - for central post-stroke pain, 172
 - for fibromyalgia, 212
 - for painful diabetic sensorimotor polyneuropathy, 106–13
 - for spinal cord injury pain, 150
 - role in neuropathic pain treatment, 217
- See also* tricyclic antidepressants; SNRIs; SSRIs *and* specific drugs.
- antihistamines, 80
- anti-inflammatory cytokines, 84
- anxiety, 328–9
- arachidonic acid, 79
- 2-arachidonylethanolamide (2-AG), 254
- aspartate, 147
- assessment tools, 1–2
- asthma, 80
- ATP (adenosine-5'-triphosphate), 77–9
- autonomic tests, 16, 20–1
- autotomy
- animal model, 33–8
- axial back pain
- spinal cord stimulation study, 277
- back pain generators, 130
- baclofen, 152, 186, 281
- balanced analgesia, 290
- balneotherapy, 210
- Beck Depression Inventory (BDI-II), 3
- behavioral interventions for sleep disorders, 325
- benzodiazepines, 342
- betamethasone, 201
- biofeedback, 325
- biomarkers for chronic pain, 342
- biomarkers for neuropathic pain, 347–8
- biopsies, 18–19, 103, 184–5

Cambridge University Press

978-1-107-02371-0 - Neuropathic Pain: Causes, Management, and Understanding

Edited by Cory Toth MD and Dwight E. Moulin MD

Index

[More information](#)

Index

- bisphosphonates, 185
 body diagrams, 5
 bone imaging, 184
 borellia (Lyme disease), 135
 botulinum toxin injections, 186, 269–70
 brachial plexitis, 138–9
 brachial plexus, 136–9
 bradykinin, 77–8
 brain derived neurotrophic factor (BDNF), 58, 77, 81, 147
 brain stimulation therapies, 349–50
 Brief Pain Inventory (BPI), 305, 316
 Short Form, 192
 brush allodynia, 5
 buprenorphine, 196, 240
 bupropion, 127
 Bushi (Japanese herbal medicine), 83
 calcitonin, 185, 294
 calcitonin-gene related peptide (CGRP), 58
 calcium channel blockers
 for painful diabetic sensorimotor polyneuropathy, 113
 calcium channels
 drug targeting, 344
 Canadian Pain Society, 225, 243
 cancer incidence, 120
 cancer pain management, 80
 adjuvant analgesics (co-analgesics), 197–202
 analgesic ladder, 192–3
 approach to, 202
 buprenorphine, 196
 codeine, 193–4
 combined drug therapies, 295
 dihydrocodeine, 194
 fentanyl, 195–6
 hydromorphone, 195
 intrathecal drug therapy, 280
 methadone, 196–7
 morphine, 194–5
 opioids for mild to moderate pain, 193–4
 opioids for moderate to severe pain, 194–7
 oxycodone, 195
 pharmacological treatments for neuropathic pain, 192–202
 tapentadol, 197
 tramadol, 193
 transdermal fentanyl, 195–6
 cancer patients, 191–2
 health-related quality of life (HRQoL), 338
 cannabidiol, 114, 255
 cannabinoid clinical studies, 255–8
 cannabinoid effects
 2-arachidonylglycerol (2AG), 254
 anandamide, 254–5
 animal models of neuropathic pain, 252–5
 cancer-associated neuropathic pain, 254
 cannabidiol, 255
 central neuropathic pain models, 254
 chemotherapy-induced neuropathic pain models, 253
 diabetic neuropathy models, 257
 endogenous cannabinoids, 254–5
 HIV neuropathic pain models, 253
 nerve injury models, 252–3
 peripheral demyelination models, 253–4
 peripheral neuropathic pain models, 252–4
 cannabinoid receptors, 251–2
 drug targeting, 345
 cannabinoid signaling pathways, 249
 cannabinoids, 114, 152
 and neuropathic pain treatment, 256
 definitions, 249
 development as pharmaceuticals, 249
 endogenous cannabinoid system, 249
 exogenous cannabinoids, 249
 for fibromyalgia, 212
 future role in neuropathic pain treatment, 258–9
 interactions with other drugs, 255
 medical marijuana debate, 249
 role in neuroimmune function, 255
 cannabis
 history of use as medicine, 249–50
 Cannabis sativa, 249
 capsaicin, 4, 127, 201, 344
 cream, 294
 topical, 113
 carbamazepine, 113, 127, 172, 200–1, 346
 characteristics, 231
 catastrophizing, 324, 326
 in chronic pain patients, 336–7
 categorical rating scales, 316–17
 cauda equina syndrome, 135
 causalgia, 177–8
 animal model, 38
 celiac disease, 3
 celiac plexus block, 267–8
 cellular signaling. *See* Toll-like receptors.
 central immune signaling
 pharmacological targeting, 347
 central inhibitory pathways, 59–61
 central nerve injury
 animal models of neuropathic pain, 39
 central neuropathic pain
 cannabinoid clinical studies, 256
 See also central post-stroke pain;
 multiple sclerosis; spinal cord injury pain.
 central post-stroke pain
 animal model, 39
 anticonvulsant treatments, 172
 antidepressant treatments, 172
 chronic pain following stroke, 170
 clinical presentations, 171
 cortical stroke, 171
 diagnostic features, 171
 epidemiology, 170
 lenticulocapsular stroke, 171
 management, 172–4
 medullary stroke, 171
 neurostimulation therapies, 173
 opioid analgesics, 173
 pathophysiology, 171–2
 pharmacological treatments, 172–3
 sites of strokes resulting in, 170–1
 thalamic stroke, 171
 central sensitization, 51, 57–9
 central inhibitory pathways, 59–61
 definition of sensitization, 52
 future developments, 61
 neural plasticity, 58–9
 channelopathy-associated insensitivity to pain (CIP), 68
 Charcot-Marie-Tooth disease, 16
 Charcot's neuroarthropathy, 104
 chemokines, 77, 84–5, 347–8
 CCL2 (MCP-1)/CCR2, 85
 cells which express, 84
 CX3CL1 (fractalkine)/CX3CR1, 85
 inflammatory mediators, 81–2
 role in neuropathic pain, 85
 chemotactic cytokine ligand 2 (CCL2), 77
 chickenpox, 120
 children, 184
 Chinese herbal medicine, 210
 chiropractic treatment, 210
 cholecystokinin, 148
 chronic compression of the dorsal root ganglion
 animal model, 39
 chronic constriction nerve injury
 model, 38
 chronic fatigue syndrome, 21
 chronic pain
 bidirectional interaction with anxiety, 328–9

Cambridge University Press

978-1-107-02371-0 - Neuropathic Pain: Causes, Management, and Understanding

Edited by Cory Toth MD and Dwight E. Moulin MD

Index

[More information](#)

Index

- bidirectional interaction with depression, 326
- coping strategies, 3
- definition, 2
- impact on families of patients, 303
- impact on patients' lives, 302–3, 322
- range of impacts on patients, 3
- shared physiological mechanisms with depression, 326–7
- chronic pain comorbidities
 - anxiety, 328–9
 - depression, 325–8
 - impact of multiple comorbidities, 322
 - impact on quality of life, 329
 - sleep disorders, 322–5
- chronic pain syndrome, 68
- chronic pelvic pain syndrome, 273
- chronic visceral pain syndrome, 273
- ciprofloxacin, 222
- cisplatin, 200
- citalopram, 150, 172, 212, 346
- clinical examination, 13
- clinical presentation, 1–5
- clinical trials
 - importance of outcome measures, 319
- clomipramine, 106, 127, 218
- clonazepam, 127, 201
- clonidine, 4, 151–2
- coccygeal injuries, 5
- codeine, 127, 151, 193–4, 240
- cognitive behavioral therapy (CBT), 210, 325, 350
- cognitive hyperarousals, 324
- combination therapies, 222–3
- combined drug therapies, 290
 - add-on therapies, 294
 - animal models, 290–1
 - first-line treatment combinations, 292
 - for cancer pain, 295
 - for mixed nociceptive and neuropathic pain, 294–5
 - for painful DSP, 114
 - human studies, 292–5
 - including opioids, 293–4
 - including topical lidocaine patch, 292
 - principal considerations, 291–2
 - role in neuropathic pain management, 295–6
 - systemic first-line agents, 292–3
 - WHO recommendations, 290
- community resources, 312–13
- complementary therapies and alternative medicines, 210
- complex regional pain syndrome, 5, 8, 21, 257, 267, 273
- bone imaging, 184
- clinical features, 182–4
- definition, 177–9
- diagnostic criteria, 177–9
- diagnostic evaluation and testing, 184–5
- electrodiagnostic testing (EDX), 184
- epidemiology, 182
- external or environmental contributors, 180
- functional restoration, 185
- history of, 177–9
- in children, 184
- internal or intrinsic contributors, 180–2
- movement and motor abnormalities, 183
- nature of the pain, 182–3
- overlap with post-traumatic neuralgia, 178–9
- pathogenesis, 179–82
- pharmacological therapies, 185–6
- research tools, 184–5
- six Ss, 1
- small fiber neuropathy, 187
- spinal cord stimulation, 276
- sudomotor phenomena, 183
- sympathetic blockade, 186
- treatments, 185–6
- Type-I and Type-II, 177–9
- vasomotor phenomena, 183
- Composite Autonomic Scoring Scale (CASS), 20
- compound muscle action potential (CMAP), 16
- compressive radiculopathy, 130–4
- computerized tomography (CT), 19
- conotoxins, 72
- Conus geographus*, 72
- Conus magus*, 72
- coping skills
 - response to chronic pain, 336
- coping strategies in chronic pain patients, 3
- corneal confocal microscopy, 103
- corticosteroids, 125
 - adjuvant analgesics, 201
- cranial electrotherapy stimulation, 349–50
- critical limb ischemia
 - spinal cord stimulation, 276–7
- cromoglycate, 80
- cryptococcosis, 135
- CT3 (ajulemic acid), 255, 257
- cyclobenzaprine, 212
- cyclooxygenase (COX) pathway, 79
- CYP2D6 gene polymorphism, 220
- CYP2D6 genotypes, 193–4
- cytokines, 56, 347–8
- anti-inflammatory types, 77, 84
- inflammatory mediators, 81–2
- pro-inflammatory types, 77, 82–4, 91
- cytomegalovirus (CMV), 135
- damage/danger associated molecular pattern (DAMP) receptors, 92
- damage/danger associated molecular patterns (DAMPs)
 - HMGB1, 93–4
- deep brain stimulation (DBS), 153, 173, 283–7
 - complications, 286–7
 - implantation technique, 284–5
 - indications, 284
 - mechanism of action, 285–6
 - present status, 286
 - response rates, 286
 - role in neuropathic pain management, 283–4
- denial
 - as a coping strategy, 3
- depression, 3
 - bidirectional interaction with chronic pain, 326
 - comorbidity with chronic pain, 325–8
 - screening for, 326
 - screening for suicidality, 326
 - shared physiological mechanisms with neuropathic pain, 326–7
 - therapeutic considerations for chronic pain patients, 327–8
- depression-pain syndrome, 327
- desipramine, 106, 127, 150, 172, 218, 346
- desmethyclomipramine, 218
- dexamethasone, 201
- dextromethorphan, 113, 151, 173, 201
- dextropropoxyphene, 240
- diabetes mellitus
 - incidence of diabetic sensorimotor polyneuropathy (DSP), 101
 - Type 1, 73
- diabetic amyotrophy, 136
- diabetic peripheral neuropathy
 - animal models, 41
 - cannabinoid clinical studies, 257
- diabetic radiculopathy, 136
- diabetic sensorimotor polyneuropathy (DSP), 221
 - anticonvulsant drugs for painful DSP, 113
 - antidepressants for painful DSP, 106–13
 - approach to pain management, 114
 - calcium channel blockers, 113
 - combination therapy for pain, 114

Index

- diabetic sensorimotor polyneuropathy (DSP) (cont.)
 condition and pain assessment, 103
 diagnosis, 101
 diagnosis of painful DSP, 101–3
 differential diagnosis of painful DSP, 104
 glycemic management, 106
 guidelines for pain control medication, 106
 impact of painful DSP on patients, 101
 impact on quality of life, 101
 incidence in patients with diabetes, 101
 lifestyle changes, 106
 management of, 101
 management of painful DSP, 106–14
 morphological and structural features of painful DSP, 104
 neuropathic pain as complication of, 101
 non-pharmacological pain treatments, 106
 opioids for pain treatment, 113
 pathophysiology, 103
 pathophysiology of pain in, 104–6
 pathophysiology of painful DSP, 103
 pharmacological treatments for pain, 106–14
 risk factors, 101
 SNRIs for painful DSP, 113
 sodium channel blockers, 113
 surgical therapy for pain, 114
 tricyclic antidepressants (TCAs) for painful DSP, 106–13
 underdiagnosis, 101
 utilization of health resources, 101
- diagnosis of neuropathic pain
 body diagrams, 5
 chronic pain coping strategies, 3
 clinical examination, 13
 clinical role of bedside quantitative sensory testing, 8–9
 impacts of chronic pain on patients, 3
 neurological examination for pain, 4
 nutrition history, 3
 pain behaviors, 5
 pain diagrams, 2
 past medical history, 3
 patient history, 1–2, 13
 value of additional neurological examination, 7
 diagnostic grading system, 13
 diagnostic testing
- autonomic tests, 20–1
 biopsies, 18–19
 functional neuroimaging, 19–20
 neurophysiologic testing, 16–18
 quantitative sensory testing, 13–15
 structural neuroimaging, 19
- diazepam, 342
 diclofenac, 127
 dihydrocodeine, 194, 240
 distal symmetrical polyneuropathy
 animal model, 41
 dorsal rami, 130
 dorsal root ganglion, 130
 neurostimulation target, 277
 Douleur Neuropathique en 4
 questions (DN4), 2, 103, 316
 doxepin, 127
 cream, 294
 dronabinol, 256
 drug synergy, 290
 human studies, 292–5
 principal considerations, 291–2
 duloxetine, 113, 150, 200, 212, 347
 adverse effects, 222
 contraindications and precautions, 222
 dosage for neuropathic pain, 222
 evidence of efficacy in pain treatment, 221
 mechanisms of action, 221–2
 use in clinical practice, 222–3
 use in combination therapies, 222–3
 use in neuropathic pain treatment, 221
- dynamic mechanical allodynia, 123
 dysesthetic pain. *See* multiple sclerosis.
 dysmenorrhea, 80
- eicosanoids, 77, 79–80
 electrodiagnostic testing (EDX), 184
 electromyography (EMG), 16, 184
 emotional functioning in chronic pain patients, 336–7
 employment
 effects of chronic neuropathic pain, 338
 endorphins, 77
 enkephalinase inhibitors, 346
 epidemiology of neuropathic pain
 impact on health-related quality of life (HRQoL), 27–8
 incidence in the general population, 27
 limitations of prevalence studies, 26
 prevalence in the general population, 24–6
 quality of life studies, 24
 use of screening tools, 24
 epidural steroid injections, 268
- epileptic seizure
 role of Toll-like receptor 4 (TLR4), 93–4
- escapism
 as a coping strategy, 3
- etanercept, 82
 ethosuximide, 73
 euphol, 255
 European Association for Palliative Care (EAPC)
 analgesic ladder, 192
 European Federation of Neurological Societies (EFNS), 225, 243
 excitatory amino acids, 148
 exercise
 benefits in neurological pain, 350
 fibromyalgia therapy, 209–10
 to help insomnia, 325
 experimental autoimmune encephalomyelitis (EAE) animal model, 160–3
- facial pain
 associated with the trigeminal nerve, 5
- failed back surgery syndrome, 273
 spinal cord stimulation, 276
- famciclovir, 121, 125
 familial rectal pain syndrome, 68
 fatigue, 3
 felbamate, 151
 fentanyl, 195–6, 240
 fibromyalgia, 21, 68
 cognitive changes, 207
 diagnosis, 205–8
 differential diagnosis, 207–8
 fatigue, 206
 genetic factors, 208
 mood disorder, 207
 nature of pain, 206
 neurophysiologic changes, 208
 outcome for patients, 213
 pathogenesis, 208
 physical examination, 207
 prevalence, 205
 psychological factors, 208
 sleep disturbance, 206
 stress-related factors, 208
 symptoms, 205
 testing, 207
 triggering events, 208
 typical patient and symptoms, 206–7
- fibromyalgia treatment, 208–13
 acetaminophen, 211
 adjuvant pharmacologic treatments, 212–13
 anticonvulsants with pain-modulating effects, 212

- antidepressants with pain-modulating effects, 212
- approach to treatment, 208–9
- cannabinoid treatments, 212
- cognitive behavioral therapy (CBT), 210
- complementary and alternative medicine, 210
- exercise programs, 209–10
- multicomponent therapy, 209
- non-pharmacological treatments, 209–10
- NSAIDs, 211
- opioid treatments, 211
- outcome for patients, 213
- pain modulation, 213
- patient education, 209
- pharmacological targeting of symptoms, 213
- pharmacological treatments, 211–13
- psychological interventions, 209–10
- self-management strategies, 209
- targeting fatigue, 213
- targeting mood disorder, 213
- targeting sleep disturbance, 213
- Finnish Pain Society, 225
- fluorouracil, 200
- fluoxetine, 127, 150, 193, 212, 346
- flupirtine, 295
- flvoxamine, 172
- fractalkine, 77, 85
- functional magnetic resonance imaging (fMRI), 19–20, 348
- functional neuroimaging, 19–20
- G-protein coupled receptors
 - drug targeting, 345–6
- GABA receptors
 - drug targeting, 342
- gabapentin, 113–14, 125, 127, 150–1, 172, 200, 212, 225–6, 295, 346
 - characteristics, 226–7
 - dosing regimes, 226–7
 - drug combinations, 230–1
 - formulations, 226–7
 - pharmacokinetics, 226–7
 - role in pain management, 226
- gabapentin enacarbil (Horizant), 227
- gabapentinoids, 121, 127, 212, 225–6
 - drug combinations, 230–1
- gamma-hydroxybutyric acid (GHB), 213
- genetic polymorphisms
 - biomarkers for neuropathic pain, 348
- glial cell derived neurotrophic factor (GDNF), 77, 81
- glial cells, 94, 148
 - drug targeting, 347
- Global Impression of Change (GIC) scale, 317
- glutamate, 57, 148, 172
- glyceryl trinitrate spray, 294
- GPR-55 receptor, 252
- Gralise, 227
- guided imagery, 210, 350
- Guillain–Barré syndrome, 135
- health professionals
 - as catalyst for successful pain management, 304
 - community resources, 312
 - pain treatment guidelines, 310–12
 - professional pain associations, 312
 - resources related to pain management, 310–12
- health-related quality of life (HRQoL)
 - cancer patients, 338
 - clinical implications of chronic neuropathic pain, 338–9
 - definition, 334
 - impact of neuropathic pain, 27–8
- heat therapy, 350
- herpes zoster
 - persistent pain following, 120
- hereditary brachial plexus neuropathy, 139
- hereditary neuropathy with predisposition to pressure palsies (HNPP), 139
- heroin, 240
- herpes simplex virus (HSV), 135
- herpes zoster, 120–3
 - guidelines for prevention of post-herpetic neuralgia, 125–8
 - natural history, 124
- histamine, 77, 80
- historical perspective
 - understanding of pain, xi
- HIV, 135
 - incidence, 120
- HIV-1 infection
 - distal symmetrical polyneuropathy models, 41
- HIV-associated sensory neuropathy
 - cannabinoid clinical studies, 257
- HMGB1 (amphoterin), 93–4
- hNE. *See* Nav1.7 channel.
- homeopathy, 210
- Horizant (gabapentin enacarbil), 227
- Horner’s syndrome of the face, 21
- hydrocodone, 240
- hydromorphone, 195, 240, 281
- hydrotherapy, 210
- hyperalgesia, 52, 123, 151
- hyperesthesia, 123
- hypersensitivity
 - and development of chronic pain, 51–2
- hypervigilance towards chronic pain, 324
- hypnosis, 210, 325, 350
- IASP (International Association for the Study of Pain)
 - definition of neuropathic pain, 1, 225
- IASP Special Interest Group on Neuropathic Pain, 1, 241
 - guidelines and recommendations for pharmacological treatment, 225
- ibudilast, 347
- ID Pain tool, 316
- idiopathic acute brachial plexus neuropathy (ABN), 138–9
- illicit substances
 - as a coping strategy, 3
- illusions
 - use as therapy, 350
- imipramine, 106, 127, 150, 218, 221, 346
- immersive virtual reality, 350
- immune signaling proteins as pain biomarkers, 348
- immune system
 - functions of Toll-like receptors, 90–2
- implanted peripheral nerve stimulation, 269
- infections
 - nerve roots, 135
- inflammation
 - definition, 77
- inflammatory bowel disease, 82
- inflammatory mediators
 - anti-inflammatory cytokines, 84
 - as targets for neuropathic pain drugs, 85
 - ATP, 78–9
 - bradykinin, 77–8
 - brain derived neurotrophic factor (BDNF), 81
 - CCL2 (MCP-1)/CCR2, 85
 - chemokines, 84–5
 - COX, 79
 - CX3CL1 (fractalkine)/CX3CR1, 85
 - eicosanoids, 79–80
 - GDNF (glial cell derived neurotrophic factor), 81
 - histamine, 80
 - IL-1 β , 82
 - IL-4, 84
 - IL-6, 82–3
 - IL-10, 84
 - IL-15, 83
 - IL-17, 83

Cambridge University Press

978-1-107-02371-0 - Neuropathic Pain: Causes, Management, and Understanding

Edited by Cory Toth MD and Dwight E. Moulin MD

Index

[More information](#)

Index

- inflammatory mediators (cont.)
 IL-18, 82–3
 interferon- γ (IFN γ), 83
 leukotrienes, 79–80
 neurotrophic factors, 80–1
 NGF (nerve growth factor), 80–1
 pro-inflammatory cytokines, 82–4
 prostaglandins, 79–80
 purines, 78–9
 role in neuropathic pain, 77
 TGF β (tumor growth factor- β), 84
 TNF (tumor necrosis factor), 82
- infliximab, 82
- inherited erythromelalgia (IEM), 68
- insomnia, 3
- intensity hypothesis of pain, 51
- interferon- γ (IFN γ), 77, 83
- interleukins
 IL-1 β , 77, 82
 IL-4, 84
 IL-6, 82–3
 IL-10, 77, 84
 IL-15, 83
 IL-17, 83
 IL-18, 82–3
- International Association for the Study of Pain. *See* IASP.
- interventional approaches
 botulinum toxin injections, 269–70
 epidural steroid injections, 268
 indications for, 271
 intrathecal drug delivery, 270–1
 peripheral nerve stimulation, 269
 radiofrequency treatments, 268–9
 role in neuropathic pain treatment, 267
 sympathetic nerve blockade, 267–8
 systemic lidocaine, 271
- intervertebral discs
 compressive radiculopathy, 130–4
- intrapartum lumbosacral plexopathy, 141
- intrathecal drug delivery, 270–1
- intrathecal drug therapy, 280–3
- intravenous immunoglobulin (IVIG), 185
- ion channels, 54–5
 role in neuropathic pain pathophysiology, 65
 types and functions, 65
- itch sensation, 4
- kainate receptor
 drug targeting, 345
- ketamine, 151–2, 186, 201, 294–5
- kinins, 77–8
- lacosamide
 characteristics, 235
- lamotrigine, 113, 127, 151, 172, 200–1
 characteristics, 232
- large fiber testing, 103
- Lasegue sign, 132
- laser stimulated evoked potentials, 18
- Latin American Federation of IASP Chapters, 225
- Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), 103, 295, 316
- leukotrienes, 77, 79–80
- levetiracetam, 151, 172, 200
- levorphanol, 240
- L'hermitte's phenomenon, 166
- lidocaine, 127, 152, 173, 201, 213
 5% patches, 113
 in combination drug therapies, 292
 ointment, 113
 patch, 292
 systemic delivery, 271
- lipoygenase pathway, 79
- listening to music as pain therapy, 351
- local anesthetics
 for cancer pain, 202
See also lidocaine; interventional approaches.
- low-level laser therapy, 351
- lumbar plexus
 painful conditions, 139–42
- lumbar radiculoplexopathy, 104
- lumbar spinal stenosis, 83
- lumbar sympathetic nerve block, 267
- lumbosacral plexopathy, 141–2
- lumbosacral plexus, 139–41
- Lyme disease (borreliosis), 135
- Lyrica[®], 227–30
- magnetic resonance imaging (MRI), 19
 functional MRI (fMRI), 19–20, 348
- magnetic resonance neurography (MRN), 19, 184
- magnetoencephalography (MEG), 19–20
- MAO inhibitors, 222
- maprotiline, 127
- massage, 351
- mast cells, 80
- McGill Pain Questionnaire (MPQ), 230, 316
- meditation, 351
- MedStream[®] Programmable Infusion System, 283
- memantine, 152, 201
- Memorial Pain Assessment Card, 192
- meperidine, 240
- metabotropic G protein-coupled receptors, 55
- metabotropic glutamate receptors
 drug targeting, 345
- methadone, 196–7, 201, 240
 mode of action, 241
- methotrexate, 200
- Mexican Pain Society, 225
- mexiletine, 113, 152, 173, 201
- mianserin, 193
- mibefradil, 73
- microneurography, 17–18
- midazolam, 201
- milnacipran, 200, 212, 221, 347
- mirror box therapy, 350
- mirtazapine, 193, 221
- mixed nociceptive and neuropathic pain
 combination drug therapy, 294–5
- Montelukast, 80
- morphine, 113, 127, 151, 173, 194–5, 240, 281
- Morton's neuroma, 104
- motor cortex stimulation, 173
- Moving Beyond Pain worksheets, 310
- multi-modal analgesia, 290
- multiple sclerosis
 animal models of dysesthetic pain, 162–3
 cannabinoid clinical studies, 256
 clinical symptoms, 156
 dysesthetic pain clinical features, 156–7
 dysesthetic pain comorbidities, 159–61
 dysesthetic pain exacerbating factors, 159
 dysesthetic pain pathophysiology, 161–3
 dysesthetic pain risk factors, 159
 dysesthetic pain treatment, 163–4
 experimental autoimmune encephalomyelitis (EAE) animal model, 160–3
 forms of the disease, 156
 impact of pain on quality of life, 159–61
 L'hermitte's phenomenon, 166
 painful tonic spasms, 166
 pathological processes, 156
 primary progressive form (PPMS), 156
 relapsing-remitting form (RRMS), 156
 secondary progressive form (SPMS), 156
 spasticity, 165
 spasticity pathophysiology, 165
 spasticity treatment, 165
 trigeminal neuralgia clinical presentation, 164
 trigeminal neuralgia pathophysiology, 164

Cambridge University Press

978-1-107-02371-0 - Neuropathic Pain: Causes, Management, and Understanding

Edited by Cory Toth MD and Dwight E. Moulin MD

Index

[More information](#)

Index

- trigeminal neuralgia treatment, 165
- types of pain associated with, 156
- music as pain therapy, 351
- My Coping Strategies – Adaptive Day worksheet, 310
- My Coping Strategies – Tough Day worksheet, 310
- My Life Team List, 310
- nabilone, 114, 257
- nabiximols, 256–7
- naloxone, 173, 240
- naltrexone, 240
- NaN. *See* Nav1.9 channel.
- narcotics, 240
- national person with pain organizations, 313
- Nav β subunits, 70–1
- Nav1.3 channel, 70
- Nav1.7 channel, 68
- Nav1.8 channel, 69
- Nav1.9 channel, 70
- neck pain generators, 130
- nerve blocks, 127
 - compressive radiculopathy diagnosis, 133
 - studies, 185
- nerve conduction studies, 13, 16–17, 184
 - compressive radiculopathy diagnosis, 133
 - diagnostic tests, 103
- nerve conduction velocity (NCV), 16
- nerve fibers, 4
- nerve growth factor (NGF), 77, 80–1
 - drug targeting, 346
- nerve plexus conditions
 - brachial plexitis, 138–9
 - brachial plexus, 136–9
 - diabetic amyotrophy, 136
 - hereditary brachial plexus problems, 139
- iatrogenic surgical complications, 141
- intrapartum lumbosacral plexopathy, 141
- lumbar plexus, 139–42
- lumbosacral plexus trauma, 141
- postpartum lumbosacral plexopathy, 141
- radiation plexopathy, 138
- retroperitoneal hematoma, 141–2
- thoracic outlet syndrome, 136–8
- traumatic injury to the brachial plexus, 136
- nerve regeneration, 82
- nerve root conditions
 - cauda equina syndrome, 135
 - compressive radiculopathy, 130–4
 - diabetic amyotrophy, 136
 - diabetic radiculopathy, 136
 - infections, 135
 - neurogenic claudication secondary to spinal stenosis, 134–5
 - non-compressive radiculopathy, 135–6
 - traumatic injury to nerve roots, 135
- nerve roots, 130
- neural plasticity, 51
 - role in central sensitization, 58–9
 - role in neuropathic pain, 9–11
- neurogenic claudication secondary to spinal stenosis, 134–5
- neuroimaging
 - potential biomarkers for chronic pain, 348
- neurological examination for pain, 4–5
- neuromodulation
 - deep brain stimulation (DBS), 283–7
 - features of, 273
 - implanted peripheral nerve stimulation, 269
 - intrathecal drug therapy, 280–3
 - role in neuropathic pain management, 273
 - spinal cord stimulation, 273–80
- neuronal hypothesis of neuropathic pain, 347
- neuropathic pain
 - characteristics, 315
 - definition, 1, 13
- Neuropathic Pain Questionnaire (NPQ), 316
- Neuropathic Pain Scale (NPS), 192, 316–17
- Neuropathic Pain Symptom Inventory (NPSI), 317
- neuropathic pain treatment
 - biomarkers for neuropathic pain, 347–8
 - challenges for future developments, 341–2
 - drug targeting studies, 342–7
 - future challenges, 355
 - limitations of current treatments, 341–2
 - non-pharmacological interventions, 348–51
 - potential use of the placebo effect, 351–5
- neurophysiological testing, 16–18
- neurostimulation therapies
 - for central post-stroke pain, 173
- neurotrophic factors, 77, 80–1
 - drug targeting, 346
- neurotrophin receptors, 55–6
- neurotrophins, 77
- NMDA (N-methyl-D-aspartate) receptor, 147–8
 - drug targeting, 345
- NMDA receptor antagonists, 151–2, 201
- nociception
 - first and second pains, 53
- nociceptor hyperexcitability, 54
- non-compressive radiculopathy, 135–6
- non-pharmacological interventions, 348–51
 - acupuncture, 349
 - brain stimulation, 349–50
 - cognitive behavioral therapy (CBT), 350
 - cranial electrotherapy stimulation, 349–50
 - exercise, 350
 - guided imagery, 350
 - heat therapy, 350
 - hypnosis, 350
 - immersive virtual reality, 350
 - listening to music, 351
 - low level laser therapy, 351
 - massage, 351
 - meditation, 351
 - mirror box therapy, 350
 - repetitive transcranial magnetic stimulation (rTMS), 349
 - spinal cord stimulation, 350
 - transcranial direct current stimulation, 349
 - transcutaneous electrical nerve stimulation (TENS), 349
 - use of illusions, 350
- nortriptyline, 106–13, 127, 150, 172, 218, 346
- NSAIDs (non-steroidal anti-inflammatory drugs), 106, 125, 127, 211
- number needed to treat (NNT), 317
- numerical rating scale (NRS), 1, 192, 316–17
- nutrition history, 3
- olanzapine, 193
- opioid addiction, 245
- opioid analgesia
 - and TLR4 activation, 95–6
- opioid hyperalgesia, 95–6, 244
- opioid-induced endocrinopathy, 244
- Opioid Manager™, 245
- opioid receptors, 240
 - drug targeting, 346
- Opioid Risk Tool, 245

Index

- opioid treatment agreements, 245
- opioids, 121
- addiction risk, 245
 - adverse effects, 243–4
 - clinical practice guidelines for neuropathic pain, 241–3
 - combined therapies for neuropathic pain, 246
 - complications, 244
 - conducting an n-of-1 opioid trial, 245–6
 - controversy over prescription, 301
 - dosage, 246
 - for central post-stroke pain, 173
 - for fibromyalgia, 211
 - for painful diabetic sensorimotor polyneuropathy (DSP), 113
 - for post-herpetic neuralgia, 125, 127
 - for spinal cord injury pain, 151
 - in combined drug therapies, 293–4
 - key points for neuropathic pain therapy, 246
 - neuropathic pain meta-analyses, 241
 - neuropathic pain randomized trials, 241
 - neuropathic pain systematic reviews, 241
 - neuropathic pain therapeutic trial procedure, 245–6
 - risk of overdose, 244
 - use in neuropathic pain conditions, 241
- opioid types, 240
- opium poppy (*Papaver somniferum*), 240
- OPQRST method, 1
- orofacial neuropathic pain
- animal models, 41–4
- osteoarthritis, 104
- osteoporosis, 184
- outcome measures
- Brief Pain Inventory (BPI), 316
 - categorical rating scales, 316–17
 - Global Impression of Change (GIC) scale, 317
 - importance in clinical trials, 319
 - McGill Pain Questionnaire (MPQ), 316
 - need for optimal assessment of neuropathic pain, 315
 - neuropathic pain characteristics, 315
 - Neuropathic Pain Scale (NPS), 316–17
 - Neuropathic Pain Symptom Inventory (NPSI), 317
 - number needed to treat (NNT), 317
 - numerical rating scale (NRS), 316–17
- pain intensity scales and questionnaires, 316
- Pain Quality Assessment Scale, 317
- proportion of responders, 317
- quantitative sensory testing (QST), 317–19
- screening tools for neuropathic pain, 316
- specific neuropathic pain scales, 316–17
- temporal aspects of pain, 317
- use of rescue medication, 317
- Visual Analog Scale (VAS), 316–17
- oxcarbazepine, 113, 127, 200–1, 346
- characteristics, 231–2
- oxidative stress, 73
- oxycodone, 113, 151, 195, 240
- oxycodone/acetaminophen, 127
- oxymorphone, 240
- Pacinian corpuscles, 4
- pain behaviors, 5
- pain diagrams, 2
- Pain Disability Index (PDI) questionnaire, 3
- pain intensity scales and questionnaires, 316
- pain journal or diary, 305–6
- pain management courses, 312
- pain management plan, 310
- pain perception
- and SCN9A polymorphism, 68
- Pain Quality Assessment Scale, 317
- pain-related evoked potentials, 18
- pain-related reflexes, 18
- pain tolerance, 4
- pain treatment guidelines, 310–12
- PainDetect tool, 316
- painful diabetic sensorimotor polyneuropathy (DSP).
- See diabetic sensorimotor polyneuropathy (DSP).
- painful HIV-associated sensory neuropathy
- cannabinoid clinical studies, 257
 - palmitoyl ethanolamide, 254, 257
 - parecoxib, 255
 - paroxetine, 150, 193, 212, 346
 - paroxysmal extreme pain disorder (PEPD), 68
- Parsonage–Turner syndrome, 138–9
- partial nerve ligation model, 38
- pathogen associated molecular pattern (PAMP) receptors, 92
- pathophysiology of neuropathic pain
- ion channel types and functions, 65
 - role of ion channels, 65
 - voltage-gated calcium channels, 71–4
- voltage-gated sodium channels, 65–71
- See also inflammatory mediators.
- Patient Health Questionnaire (PHQ-9), 3
- patient history, 1–2, 13
- patient perspective
- barriers to accessing effective pain management, 300–2
 - barriers to adaptation and coping, 302
 - building capacity for effective pain management, 303–4
 - conceptual barriers to pain management, 300
 - controversies over prescribing opioids, 301
 - dismissive attitudes affect treatment, 300–1
 - educational shortfalls about pain and pain management, 302
 - general misunderstanding of chronic pain, 300
 - global impact of undermanaged chronic pain, 302–3
 - healthcare system inadequacies, 301
 - health professional as catalyst for successful pain management, 304
 - impact on family, 303
 - impact on the person living with chronic pain, 302–3
 - lack of awareness of how pain affects patients, 300
 - living with neuropathic pain, 299
 - people with pain as part of the solution, 304
 - potential for improvement in pain management, 313
 - stigma associated with chronic pain, 300–1
 - unrealistic patient expectations of medicine and technology, 302
- patient tools, 304–13
- Brief Pain Inventory (BPI), 305
 - community resources, 313
 - Moving Beyond Pain worksheets, 310
 - My Coping Strategies – Adaptive Day, 310
 - My Coping Strategies – Tough Day, 310
 - My Life Team List, 310
 - national person with pain organizations, 313
 - pain information websites, 312–13
 - pain journal or diary, 305–6
 - pain management courses, 312
 - personalized pain management plan, 310

Cambridge University Press

978-1-107-02371-0 - Neuropathic Pain: Causes, Management, and Understanding

Edited by Cory Toth MD and Dwight E. Moulin MD

Index

[More information](#)

Index

- support for health professionals, 310–12
- peripheral arterial disease, 273
 - spinal cord stimulation, 276–7
- peripheral nerve injury
 - animal models of neuropathic pain, 33–9
- peripheral nerve stimulation
 - by implanted device, 269
- peripheral neuropathic pain
 - cannabinoid clinical studies, 256–7
 - See also* diabetic sensorimotor neuropathy (DSP); nerve plexus conditions; nerve root conditions; post-herpetic neuralgia.
- peripheral neuropathy, 273
 - nutritional issues, 3
- peripheral processes
 - spinal cord injury pain, 147
- peripheral sensitization, 51
 - cytokines, 56
 - definition and characteristics, 52
 - definition of sensitization, 52
 - future developments, 61
 - inflammatory mediators, 52–3
 - mechanisms, 53–4
 - metabotropic G-protein coupled receptors, 55
 - neurotrophin receptors, 55–6
 - nociceptor hyperexcitability, 54
 - role of ion channels, 54–5
- pernicious anemia, 3
- Personal Therapy Manager[®], 282
- personalized pain management plan, 310
- phantom limb pain, 273
- pharmacological treatment
 - guidelines and recommendations, 225
- pharmacological targeting studies, 342–7
 - alpha adrenergic receptors, 346
 - AMPA receptor, 345
 - anticonvulsants, 346
 - calcium channels, 344
 - cannabinoid receptors, 345
 - central immune signaling, 347
 - G-protein coupled receptors, 345–6
 - GABA receptors, 342
 - ion channels, 342–5
 - kainate receptor, 345
 - metabotropic glutamate receptors, 345
 - nerve growth factor (NGF), 346
 - neurotrophic factors, 346
 - NMDA receptor, 345
 - opioid receptors, 346
 - SNRIs (serotonin norepinephrine reuptake inhibitors), 347
 - sodium channels, 342–4
 - SSRIs (selective serotonin reuptake inhibitors), 347
 - tricyclic antidepressants (TCAs), 346
 - TRPV1 receptor, 344–5
- phenobarbital, 200
- phenytoin, 127, 172, 200
 - characteristics, 233–4
- physical functioning
 - impact of chronic pain, 336
- Pilates, 210
- piriformis syndrome, 5
- placebo effect, 351–5
- plantar fasciitis, 104
- PN1. *See* Nav1.7 channel.
- poor metabolic conversion (PM), 127
- positron emission tomography (PET), 19–20, 348
- post-herpetic neuralgia, 1, 120, 273
 - approach to prevention and treatment, 121
 - cannabinoid clinical studies, 257
 - clinical effectiveness of
 - pharmacological agents, 124–5
 - clinical features of herpes zoster, 122–3
 - clinical vignette, 5
 - definition, 120
 - guidelines for prevention and treatment, 125–8
 - herpes zoster precursor, 120
 - incidence, 120
 - management approaches, 123–4
 - natural history, 124
 - putative pain mechanisms, 123
 - topical agents, 127
- postpartum lumbosacral plexopathy, 141
- post-surgical neuropathy
 - cannabinoid clinical studies, 257
- post-traumatic neuralgia
 - bone imaging, 184
 - clinical features, 182–4
 - definitions, 177–9
 - diagnostic evaluation and testing, 184–5
 - electrodiagnostic testing (EDX), 184
 - epidemiology, 182
 - external or environmental contributors, 180
 - functional restoration, 185
 - in children, 184
 - internal or intrinsic contributors, 180–2
 - movement and motor abnormalities, 183
 - nature of the pain, 182–3
 - overlap with complex regional pain syndrome, 178–9
 - pathogenesis, 179–82
 - pharmacological therapies, 185–6
 - research tools, 184–5
 - small fiber neuropathy, 187
 - sudomotor phenomena, 183
 - sympathetic blockade, 186
 - treatments, 185–6
 - vasomotor phenomena, 183
- post-traumatic neuropathy
 - cannabinoid clinical studies, 257
- pramipexole, 213
- prednisolone, 201
- prednisone, 201
- pregabalin, 113, 125, 127, 150–1, 172, 200, 212, 221, 225–6, 346
 - characteristics, 227–30
 - drug combinations, 230–1
 - pharmacokinetics, 227–9
 - role in pain management, 227–30
- Prialt, 72, 74
- professional pain associations, 312
- Prometra[®] pump, 283
- propentofylline, 85, 347
- propofol, 173
- prostaglandins, 77, 79–80
- psoriasis, 82
- psychological interventions for sleep disorders, 325
- psychotherapy, 325
- purines
 - inflammatory mediators, 78–9
- Qigong, 210
- quality of life
 - cancer patients, 338
 - catastrophizing, 336–7
 - clinical implications of chronic neuropathic pain, 338–9
 - coping skills, 336
 - definition, 334
 - effects of neuropathic pain, 24
 - emotional functioning in chronic pain patients, 336–7
 - impact of chronic pain
 - comorbidities, 329
 - impact of neuropathic pain, 27–8
 - physical functioning in chronic pain patients, 336
 - role and social functioning, 338
- quantitative sensory and autonomic response testing (QSART), 103
- quantitative sensory testing (QST), 13–16, 185, 317–19
 - bedside method, 8
 - caveats for interpretation, 11
 - clinical role in neuropathic pain
 - diagnosis, 8–9
 - effects of cannabinoid
 - administration, 257–8

Index

- quantitative sensory testing (QST) (cont.)
 general principles, 317–18
 in intervention trials, 318–19
 normative data, 317–18
 role of neural plasticity, 9–11
 Quantitative Sudomotor Axon Reflex Test (QSART), 21
- radiation plexopathy, 138
 radiofrequency treatments, 268–9
 RAGE receptor, 103
 reactive oxygen species, 77, 103
 reflex sympathetic dystrophy, 177–8
 refractory angina pectoris, 273
 spinal cord stimulation, 276
 relaxation therapy, 325
 repetitive transcranial magnetic stimulation (rTMS), 349
 Resting Sweat Output (RSO) test, 21
 retroperitoneal hematoma, 141–2
 rheumatoid arthritis, 82
 risperidone, 193
 ritanserin, 213
 rumination, 324
- sciatica, 82, 132
 SCN3A gene, 70
 SCN9A gene polymorphism, 68
 SCN11A gene, 69
 screening
 for anxiety, 328
 for depression, 326
 for suicidality, 326
 screening tools for neuropathic pain, 316
 Seddon's neurotmesis, 186
 selective serotonin reuptake inhibitors. *See* SSRIs.
 sensitization, 51–2
 See also central sensitization; peripheral sensitization.
 sensory mapping
 clinical vignette, 7–8
 sensory nerve action potential (SNAP), 16
 sensory neuron specific (SNS) channel. *See* Nav1.8.
 sensory pain testing. *See* quantitative sensory testing (QST).
 sensory systems
 and development of chronic pain, 51–2
 sensory threshold, 4
 serotonin norepinephrine reuptake inhibitors. *See* SNRIs.
- serotonin syndrome, 193, 197, 212, 221
 sertraline, 150, 193, 212, 346
 short bowel syndrome, 3
 single photon emission computed tomography (SPECT), 19–20
 six Ss of complex regional pain syndrome, 1
 sleep disorders, 322–5
 small fiber disease, 102–3
 small fiber neuropathy, 4, 21, 68
 complex regional pain syndrome, 187
 post-traumatic neuralgia, 187
 small fiber testing, 102
 SNRIs (serotonin norepinephrine reuptake inhibitors), 113, 121, 127, 200, 212
 adverse effects, 222
 contraindications and precautions, 222
 dosage for neuropathic pain, 222
 evidence of efficacy in pain treatment, 221
 for spinal cord injury pain, 150
 mechanisms of action, 221–2
 neuropathic pain studies, 347
 role in neuropathic pain treatment, 217
 use in clinical practice, 222–3
 use in combination therapies, 222–3
 use in neuropathic pain treatment, 221
 social functioning
 effects of chronic neuropathic pain, 338
 sodium channel blockers
 for painful diabetic sensorimotor polyneuropathy, 113
 sodium channels
 drug targeting, 342–4
 sodium oxybate, 212
 sodium valproate, 294
 somatosensory evoked potentials, 16
 spa therapy, 210
 spared nerve injury model, 39
 specificity hypothesis of pain, 51
 sphenopalatine ganglion block, 267
 spinal cord injury
 animal models, 39
 spinal cord injury pain
 anatomic changes following injury, 149
 approach to treatment, 149–50
 cannabinoid clinical studies, 256
 central processes in neuropathic pain, 147–8
 classification, 149
 impact on patients, 145
 location of pain in relation to injury level, 149
 modulatory role of descending pathways, 149
 neurosurgical interventions, 153
 non-pharmacological treatment, 152–3
 pain pathway, 146–7
 pathophysiologic mechanisms of neuropathic pain, 146
 peripheral processes in neuropathic pain, 147
 pharmacological treatment, 149–52
 prevalence of, 145
 regional blocks, 152
 role of CNS glial cells, 148
 role of the NMDA receptor, 147–8
 secondary pathological changes, 149
 spinal inhibitory control, 148
 stimulation techniques, 152–3
 symptoms of neuropathic pain, 146
 treatment, 149–53
 spinal cord stimulation, 106, 153, 273–80, 350
 axial back pain study, 277
 challenges, 280
 complex regional pain syndrome, 276
 complications, 279
 cost-effectiveness, 277
 costs, 277
 critical limb ischemia, 276–7
 effects of delay on outcome, 280
 failed back surgery syndrome, 276
 future directions, 277
 hardware, 273–4
 implantation procedure, 273–5
 implanted pulse generator design, 273
 indications, 273, 276–7
 intraspinal targets, 277
 mechanism of action, 275–6
 MRI lead incompatibility, 280
 new devices, 277
 optimizing therapy, 277–80
 outcomes and wait times, 280
 patient selection, 277
 peripheral arterial disease, 276–7
 refractory angina pectoris, 276
 role in neuropathic pain management, 273
 spinal nerve ligation model, 38
 spinal nerve roots, 130
 spinal stenosis
 neurogenic claudication caused by, 134–5
 treatment, 135

- splanchnic nerve block, 267
 spontaneous burning pain
 animal model, 38
 Spurling's maneuver, 132
 SSRIs (selective serotonin reuptake inhibitors), 127, 172, 197, 212, 217
 for spinal cord injury pain, 150
 neuropathic pain studies, 347
 stellate ganglion block, 267
 steroids, 73
 stroke. *See* central post-stroke pain.
 structural neuroimaging, 19
 substance P, 57
 Sudeck's atrophy, 184
 suicidality
 screening for, 326
 suicidal ideation, 3
 superconducting quantum
 interference devices (SQUIDS), 19
 surgical therapy for DSP, 114
 sympathetic nerve blockade, 267–8
 syndrome of inappropriate secretion
 of antidiuretic hormone
 (SIADH), 113
 syphilis, 135
 systemic lidocaine, 271
- Tai Chi, 210
 tamoxifen, 200
 tapentadol, 197, 211, 240
 mode of action, 240
 temporal aspects of pain, 317
 terguride, 213
 terminology relating to neuropathic
 pain, 4–5
 tetrahydrocannabinol (THC), 114, 152
 TGF β (transforming growth factor- β),
 77
 TGF β (tumor growth factor- β), 84
 thalamic pain syndrome, 80
 thalassotherapy, 210
 Theiler's murine encephalitis virus
 (TMEV) model, 163
 Thermoregulatory Sweat Test (TST), 21
 thoracic outlet syndrome, 136–8
 tiagabine, 151
 TNF (tumor necrosis factor), 77, 82
 tocilizumab, 83
 Toll-like receptor 4 (TLR4), 92
 and HMGB1, 93–4
 and the nervous system, 93
 endogenous nervous system
 agonists, 93
 neuronal TLR4 and epileptic
 seizure, 93–4
 opioid analgesia and TLR4
 activation, 95–6
 TLR4 signal pathway and
 neuropathic pain, 94–5
- Toll-like receptors, 90–2
 topical anesthetic, 113
 topical capsaicin, 113
 topical nitrate spray, 113
 topiramate, 113, 127, 151, 172,
 200–1
 characteristics, 233
 toxoplasmosis, 135
 tramadol, 113, 127, 151, 193, 197,
 211–12, 240
 mode of action, 240
 transcranial direct current stimulation,
 210, 349
 transcranial magnetic stimulation
 (TMS), 106, 173, 210
 repetitive TMS (rTMS), 349
 transcutaneous electrical nerve
 stimulation (TENS), 106, 127,
 152–3, 349
 transdermal fentanyl, 195–6
 traumatic injury
 brachial plexus, 136
 damage to nerve roots, 135
 lumbosacral plexus, 141
 trazodone, 127
 tricyclic antidepressants (TCAs),
 106–13, 121, 127, 201
 adverse effects, 219
 clinical pain relief, 218
 contraindications and precautions,
 219
 dosing for neuropathic pain, 219
 drug–drug interactions, 219–20
 evidence of efficacy in pain
 treatment, 217–18
 for cancer pain, 197
 for central post-stroke pain,
 172
 for fibromyalgia, 212
 for post-herpetic neuralgia, 127
 for spinal cord injury pain, 150
 interactions of TCAs, 219–20
 mechanisms of action, 218–19
 neuropathic pain studies, 346
 polymorphisms and interactions in
 the CYP2D6 enzyme, 220
 role in neuropathic pain treatment,
 217
 safety monitoring, 219
 serotonin syndrome, 221
 use in clinical practice for
 neuropathic pain, 219–21
 use in combination therapy, 221
 trigeminal nerve
 facial pain associated with, 5
 trigeminal neuralgia, 80
 in multiple sclerosis, 164–5
 trigeminal neuropathic pain
 animal models, 41–4
- TRP (transient receptor potential)
 channels, 53
 TRPV receptors, 4
 TRPV1 receptor, 53
 drug targeting, 344–5
 tuberculosis (TB), 135
- ultrametabolic conversion (UM),
 127
 ultrasound imaging, 184
 unmyelinated nerve fibers, 4
- valacyclovir, 121, 125
 valdecoxib, 255
 valproate, 113, 127
 valproic acid, 151, 200
 characteristics, 234–5
 vanilloids, 344
 varicella vaccination, 120, 128
 varicella zoster virus (VZV),
 120, 135
 vascular claudication, 104
 vegan diet, 3
 venlafaxine, 113, 127, 150, 172, 193,
 200–1, 212
 adverse effects, 222
 contraindications and precautions,
 222
 dosage for neuropathic pain, 222
 evidence of efficacy in pain
 treatment, 221
 mechanisms of action, 221–2
 use in clinical practice, 222–3
 use in combination therapies,
 222–3
 use in neuropathic pain treatment,
 221
 ventral rami, 130
 vigabatrin, 151
 vincristine-induced painful
 neuropathy
 animal model, 41
 Visual Analog Scale (VAS), 1, 316–17
 vitamin B1, 3
 vitamin B6, 3
 vitamin B12 levels
 and peripheral neuropathy, 3
 voltage-gated calcium channels
 as neuropathic pain drug targets,
 74
 HVA (high voltage activated)
 channels, 71–2
 L-type, 71–2, 74
 LVA (low voltage activated)
 channels, 71–2
 N-type, 71–3
 P-type, 71–2
 Q-type, 71–2
 R-type, 71–2

Index

voltage-gated calcium channels (cont.) T-type, 71–4 types of, 71–2	Nav1.8 channel, 69 Nav1.9 channel, 70 sodium channel complement, 71 structure and function, 65–7	classification of opioids, 240 combined drug therapy recommendations, 290
voltage-gated ion channels, 54–5		Zafirlukast, 79
voltage-gated sodium channels activation states, 67–8 as neuropathic pain drug targets, 74 Nav β subunits, 70–1 Nav1.3 channel, 70 Nav1.7 channel, 68	websites pain information for patients, 312–13 wind-up phenomenon, 151 World Health Organization (WHO) analgesic ladder, 192–3	ziconotide, 281 Zileuton, 80 zonisamide, 151, 172, 200 characteristics, 233 zoster prevention vaccine, 121 zoster sine herpete, 121